Long-term cardiovascular consequences of fetal growth restriction: biology, clinical implications, and opportunities for prevention of adult disease
Open accessAbstract
In the modern world, cardiovascular disease is a leading cause of death for both men and women. Epidemiologic studies consistently have suggested an association between low birthweight and/or fetal growth restriction and increased rate of cardiovascular mortality in adulthood. Furthermore, experimental and clinical studies have demonstrated that sustained nutrient and oxygen restriction that are associated with fetal growth restriction activate adaptive cardiovascular changes that might explain this association. Fetal growth restriction results in metabolic programming that may increase the risk of metabolic syndrome and, consequently, of cardiovascular morbidity in the adult. In addition, fetal growth restriction is strongly associated with fetal cardiac and arterial remodeling and a subclinical state of cardiovascular dysfunction. The cardiovascular effects ocurring in fetal life, includes cardiac morphology changes, subclinical myocardial dysfunction, arterial remodeling, and impaired endothelial function, persist into childhood and adolescence. Importantly, these changes have been described in all clinical presentations of fetal growth restriction, from severe early- to milder late-onset forms. In this review we summarize the current evidence on the cardiovascular effects of fetal growth restriction, from subcellular to organ structure and function as well as from fetal to early postnatal life. Future research needs to elucidate whether and how early life cardiovascular remodeling persists into adulthood and determines the increased cardiovascular mortality rate described in epidemiologic studies.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Fetal growth restriction is associated with metabolic programming that increases the risk of future development of metabolic syndrome and consequent cardiovascular and endocrine diseases.
“It has been associated with metabolic programming that increases the risk of future development of metabolic syndrome and consequent cardiovascular and endocrine diseases.11,12”
From Society for Maternal-Fetal Medicine Consult Series #52: Diagnosis and management of fetal growth restriction (2020) · cites this paper as [12]
The Abstract states that fetal growth restriction causes metabolic programming that may increase the risk of metabolic syndrome and, consequently, adult cardiovascular morbidity. The Fetal Programming of Adult Cardiovascular Disease section also discusses diabetes as a metabolic disease, but does not say that metabolic syndrome leads to endocrine diseases. The claim therefore adds an unsupported consequence and is more certain than the paper’s qualified statement. (LLM, conf=0.88)
Experimental — accuracy not yet measuredPreterm birth and FGR are clinically observable sentinel phenotypes that may reflect several adverse maternal-placental-fetal pathways and are themselves associated with long-term cardiometabolic risk.
“Preterm birth and FGR are clinically observable sentinel phenotypes that may reflect several adverse maternal–placental–fetal pathways and are themselves associated with long-term cardiometabolic risk [97,98,99,100,101].”
From Placental Pathophysiology and Developmental Programming of Adult Cardiometabolic Risk: A Narrative Review of Pregnancy Exposures (2026) · cites this paper as [98]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 158 · Cited by 362
Research works printed but not linked: 4
- [39]39. Tang X, Hernandez-Andrade E, Ahn H, et al. Intermediate diastolic velocity as a parameter of cardiac dysfunction in growth-restricted fetuses. Fetal Diagn Ther 2016;39:28-39.
- [63]63. Expert Reviews ajog.org S874 American Journal of Obstetrics & Gynecology FEBRUARY 2018
- [147]147. Gilsbach R, Preissl S, Grüning BA, et al. Dynamic DNA methylation orchestrates car- diomyocyte development, maturation and dis- ease. Nat Commun 2014;5:5288.
- [157]157. Skilton MR, Ayer JG, Harmer JA, et al. Impaired fetal growth and arterial wall thickening: a randomized trial of u-3 supplementation. Pe- diatrics 2012;129:e698-70. 110. ajog.org Expert Reviews
- Authors
- Crispi, F., Miranda, J., & Gratacós, E.
- Affiliations
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Corresponding author
- Crispi, Fatima
- Venue
- American Journal of Obstetrics and Gynecology
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 218
- Issue
- 2
- Pages
- S869-S879
- ISSN
- 0002-9378 (ISSN-L)
- OpenAlex
- W2790251179
- Semantic Scholar
- 434e5fa106b65f2280306f9bac3220dfce5721b8
- Cited by
- 362
- References
- 158
- Citations by year
- 2026: 38 · 2025: 51 · 2024: 44 · 2023: 43 · 2022: 47 · 2021: 52 · 2020: 50 · 2019: 25 · 2018: 12
- FWCI
- 6.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- American Journal of Obstetrics and Gynecology (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by-nc-nd)
- Funders
- European Commission (2013‐0040, Framework Agreement number: 2013-0040)
- Cerebra
- Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona
- Agència de Gestió d'Ajuts Universitaris i de Recerca
- Instituto de Salud Carlos III (INT16/00168, PI15/00130, PI14/, PI14/00226, PI15/00130, PI14/00226)
- European Regional Development Fund
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Birth, Development, and Health
- Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy and preeclampsia studies
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Cardiovascular Conditions and Treatments
- Keywords
- fetal growth restriction, cardiovascular disease, low birth weight, metabolic programming, metabolic syndrome, arterial remodeling, subclinical cardiac dysfunction, endothelial dysfunction, cardiovascular mortality, early-onset fetal growth restriction, late-onset fetal growth restriction
- MeSH terms
- Adaptation, Physiological, Adult, Cardiovascular Diseases, Female, Fetal Growth Retardation, Humans, Male, Pregnancy, Prenatal Exposure Delayed Effects, Ventricular Remodeling, Epigenesis, Genetic, Fetal Development, Atrial Remodeling, Vascular Remodeling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review